Researchers from the Institute for Molecular Bioscience (IMB) at The University of Queensland (UQ) have been pioneers in the discovery, applications and bio-engineering of a novel class of small, cyclic peptides called cyclotides. The platform enables the design and development of peptide drugs that are more stable and potentially orally bioavailable without compromising specificity or functionality. Potential applications include both peptide therapeutics and delivery of antigens for vaccination.

UniQuest Contact: 

Stephen Earl

Position: 
Director, Commercial Engagement - Therapeutics (Health)
Mobile phone: 
+61 421 780 689
Work phone: 
+61 (7) 3365 4037